– USA, CA – Biocom California, the association representing the California life science industry, today announced the appointment of Dr. Neil Bence (Ph.D.) and Connor Bates to its board of governors.
Concurrently, Biocom announces the appointments of former members of its board of governors, Joydeep Ganguly, Dr. Julie Gilmore (Ph.D.), and Matt Bresnahan to its Board of Directors.
“We carefully select our board members to ensure we consistently have the most dynamic, highly qualified and exceptional leaders in the life science industry on our team to aid us in meeting the evolving needs of California’s biotechnology community. I’m fully confident Dr. Bence and Mr. Bates’ talents and depths of experience will prove invaluable as we continue to drive California’s life science industry forward,” said CEO, Joe Panetta.
He added, “The new appointees to our board of directors have demonstrated a consistent track record of excellence in our industry and have contributed greatly as members of our board of governors. I look forward to their participation on our board of directors and am certain they will continue to be vital counsel for Biocom California.”
About Neil Bence
Neil Bence serves as VP and head of oncology discovery in Research & Early Development at Bristol Myers Squibb, where he oversees an oncology discovery team at the Oncogenesis Thematic Research Center and serves as site head for the company’s San Diego location. Prior to joining Bristol Myers Squibb, Neil served as the head of biology at Nurix Therapeutics in San Francisco, where he oversaw research for multiple oncology and immuno-oncology programs now in clinical development. He also worked at Millennium and Takeda Pharmaceuticals in Cambridge, Massachusetts, helping to advance multiple programs for hematological and solid tumor oncology indications.
Neil received his bachelor’s degree from the University of California, Davis, and his Ph.D. in biological sciences from Stanford University.
About Connor Bates
Connor Bates is currently VP and general manager at BD Medication Management Solutions, where he leads the development and execution of the company’s global infusion strategy. Earlier in his career, Connor held multiple cross-functional roles including marketing, strategic planning, supply chain management, new product development, process engineering and manufacturing operations.
Connor received his B.S. in mechanical engineering from Kettering University and his MBA from Harvard Business School.
About Biocom California
Biocom California is the leader and advocate for California’s life science sector. We work on behalf of more than 1,700 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs.
Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.
For more information: https://www.biocom.org/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
